FIELD: medicine.
SUBSTANCE: invention represents an anti-tumour agent containing glucocorticoid hormone in an amount of 0.3 mcg%-40 mcg%, very low-density lipoproteins in an amount to provide the apolipoprotein E content in a formulation of not less than 1 mg%, and additionally a physiologically acceptable solvent, which can be used to inhibit the tumour growth by initiating the tumour cell apoptosis.
EFFECT: higher effectiveness of the antitumour agent and extended indications for use.
2 cl, 3 ex, 6 tbl, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION FOR KILLING TNF-α-SENSITIVE TUMOR CELLS | 2002 |
|
RU2209078C1 |
RECOMBINANT DNA PROVIDING IN COMPOSITION OF PLASMID VECTOR SYNTHESIS IN CELLS OF Ecoli OF CHIMERIC PROTEIN - A-I APOLIPOPROTEIN OF HUMAN BEING | 2014 |
|
RU2573930C1 |
ENDOGENIC PHARMACEUTICAL COMPOSITION PREPARED ON BASIS OF GOAL-SEEKING ACTIVATION OF HUMORAL MEDIATORS OF BRAIN CORTEX NERVE ENDING | 2003 |
|
RU2244928C2 |
AGENT INHIBITING MULTIPLE DRUG RESISTANCE OF TUMOUR CELLS | 2012 |
|
RU2494742C1 |
MEANS TO INHIBIT TUMOR GROWTH | 1995 |
|
RU2106146C1 |
ANTICANCER AGENT | 2011 |
|
RU2455011C1 |
METHOD FOR TUMOUR GROWTH INHIBITION | 2012 |
|
RU2491930C1 |
METHOD FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2662354C1 |
AGENT FOR STIMULATING PROLIFERATIVE ACTIVITY OF BONE MARROW CELLS | 2023 |
|
RU2811901C1 |
ANTITUMOR AGENT | 1998 |
|
RU2145854C1 |
Authors
Dates
2015-02-10—Published
2013-12-25—Filed